Biocytogen and Singleron Enter Strategic Collaboration to Co-Develop iPSC-CAR-NK Allogeneic Cell Therapies

Recently, Biocytogen announced on its official WeChat account that it has reached a strategic cooperation agreement with Xingyiang (Shanghai) Biotechnology Co., Ltd. ("Xingyiang"). Biocytogen will provide Xingyiang with antibody sequences targeting specific antigens based on the RenMab® mouse platform for generating fully human antibody molecules, to support the development of iPSC-CAR-NK universal off-the-shelf cellular immunotherapy products. For each collaborative target, Biocytogen will receive an upfront payment, milestone payments, and sales royalties.

Biocytogen is an international biopharmaceutical company driven by innovative technologies, committed to becoming the birthplace of novel global drugs. Based on its fully proprietary RenMice platform (RenMab® and RenLite® mice), Biocytogen is implementing a large-scale antibody development program based on in vivo efficacy, the "Project Thousand Mice Ten Thousand AntibodiesTM," aiming to develop antibodies for over 1,000 potential drug targets. Currently, Biocytogen has established strategic partnerships with multiple pharmaceutical companies, including MNCs in China and abroad. In the future, the company will continue to collaborate with global partners to achieve the goal of developing First-in-class and Best-in-class innovative drugs.

Xingyiang (Shanghai) Biotechnology Co., Ltd. focuses on the research and development and industrialization of immune cell drugs. By combining independent innovation with collaborations with globally leading companies and institutions, it develops universal off-the-shelf iPSC-CAR-NK immune cell products, aiming to provide effective therapeutic drugs for cancer patients worldwide.

Editor: Eight Corners

Disclaimer: This article is a compilation of content from Pharmaron's website and does not represent the views of this platform. If there are any issues related to the content, copyright, or other problems, please contact us via the message board of this official account, and we will delete the content as soon as possible.